olmesartan medoxomil has been researched along with Diabetic Angiopathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chatzikyrkou, C; Haller, H; Menne, J; Ritz, E; Ruilope, LM; Viberti, G | 1 |
| Littlejohn, T; Neutel, JM; Qian, C; Ram, CV; Sachson, R; Shojaee, A; Stoakes, KA | 1 |
2 trial(s) available for olmesartan medoxomil and Diabetic Angiopathies
| Article | Year |
|---|---|
The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Female; Follow-Up Studies; Humans; Imidazoles; Kidney; Logistic Models; Male; Middle Aged; Odds Ratio; Olmesartan Medoxomil; Proportional Hazards Models; Renin-Angiotensin System; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome | 2014 |
Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles; Treatment Outcome | 2011 |